In short: Collagen is not proven to regrow hair or treat hair loss. Recent human trials found changes in hair condition or shaft diameter with particular collagen peptides, but they did not show new follicle growth or establish a treatment for alopecia. Lab and mouse findings cannot answer what happens in people.
Collagen is not proven to regrow hair or treat hair loss. Human studies have reported changes in hair gloss, elasticity or shaft diameter with particular collagen peptide products, but those outcomes are not the same as a higher hair count or recovery from alopecia (Kim and colleagues, 2026; Hwang and colleagues, 2026).
Hair loss has several possible causes, so an ingredient claim cannot identify the cause or show that a supplement fits it. The NHS hair loss guidance advises seeing a GP if you are worried and finding out the cause before approaching a commercial hair clinic.
Does collagen help hair growth in people?
The direct human evidence is limited and does not yet show regrowth. A 2026 randomised, placebo-controlled trial studied Korean adults with mild to moderate hair damage who did not have alopecia. After 24 weeks, the group given one low-molecular-weight collagen peptide had better measured hair gloss, tensile strength and hair diameter than the placebo group. Participants also rated aspects such as texture, fullness and appearance (Kim and colleagues, 2026).
The researchers did not report that the product increased follicle number, scalp hair density or growth rate. Stronger or wider existing fibres can affect how hair looks and feels without showing that lost hair has returned (Kim and colleagues, 2026).
Another 2026 placebo-controlled study enrolled 114 women aged 20 to 50 who had thigh cellulite and self-reported hair thinning. It found an increase in hair shaft diameter after 24 weeks with a specific fish-derived collagen peptide. The study also measured cellulite severity, skin roughness and skin elasticity. Its abstract does not report a hair-count or density outcome, and the participants were not described as having a clinician-confirmed type of alopecia (Hwang and colleagues, 2026).
These studies provide early evidence about two particular formulations and selected hair-fibre measurements. They do not establish that collagen powders, drinks, gummies, shampoos or other products produce the same changes. They also do not show that collagen reverses male or female pattern hair loss, patchy loss, scarring loss or shedding linked to illness (Kim and colleagues, 2026; Hwang and colleagues, 2026).
Why do laboratory and mouse studies get mentioned?
A 2024 study exposed cultured human dermal papilla cells and isolated human hair follicles to a low-molecular-weight fish collagen peptide. It also gave the peptide to mice. The researchers reported cell-signalling changes, growth of isolated follicles and increased coat regrowth in the mice (Kim and colleagues, 2024).
Those models explore a possible mechanism without testing clinical hair regrowth. Cells in a dish do not reproduce digestion, distribution through the body or the many causes of human hair loss. Mouse coat regrowth also cannot establish an effect on an adult human scalp. The paper describes cell, isolated-follicle and mouse experiments rather than a trial in people with alopecia (Kim and colleagues, 2024).
The laboratory paper examined a defined low-molecular-weight peptide, not collagen as a single interchangeable substance. A positive result for that material cannot be transferred to every source, molecular size, delivery route or mixed supplement without testing the product in question (Kim and colleagues, 2024).
Do skin results prove a hair benefit?
No. Collagen research often measures skin properties, and those endpoints should remain attached to skin. In the 114-woman study, improvements in cellulite severity, skin roughness and skin elasticity were separate from the reported hair-shaft measurement. Better skin elasticity does not demonstrate more scalp follicles, faster hair growth or recovery from a hair-loss condition (Hwang and colleagues, 2026).
The damaged-hair trial also reported increased scalp elasticity, but the participants did not have alopecia. Its hair findings concerned gloss, elasticity, tensile strength, diameter and subjective condition, with no measurement of new hairs in people with diagnosed hair loss (Kim and colleagues, 2026).
Neither human trial counted new follicles or tested adults with diagnosed alopecia. Product marketing may group gloss, shaft width and regrowth under "hair health", but these trials support only the named fibre measurements in their study populations (Kim and colleagues, 2026; Hwang and colleagues, 2026).
What should happen before a clinic discussion?
Start with the cause of the loss rather than a supplement label. The NHS says some hair loss is temporary, some pattern loss is inherited, and possible causes include illness, stress, cancer treatment, weight loss and iron deficiency. It advises seeing a GP if you are worried and getting an idea of the cause before considering a commercial clinic (NHS).
That assessment separates hair-fibre damage from shedding, breakage and follicle loss. It also prevents results from adults without alopecia being treated as evidence for a diagnosed condition. No hair-loss treatment works for everyone, according to the NHS, so a claim about general "hair health" should not be read as a predictable result for an individual (NHS).
If surgery later becomes part of the discussion, collagen evidence does not determine transplant suitability. The treating clinic needs to assess the type and pattern of loss, while the collagen studies above neither tested transplantation nor measured graft outcomes (Kim and colleagues, 2026; NHS: Hair transplant).
Risks and what can go wrong
Short trials cannot establish long-term safety or cover every collagen product. The damaged-hair trial reported no treatment-related adverse events over 24 weeks, but it tested one peptide in adults without alopecia. That result should not be transferred to products with different sources, processing or added ingredients (Kim and colleagues, 2026).
The larger practical risk is relying on a supplement claim while the reason for continuing hair loss remains unclear. The NHS notes that hair loss can sometimes be a sign of a medical condition and advises GP assessment when you are worried (NHS). A change in shine or fibre width would not rule out an underlying cause.
Surgery carries a different risk profile from a supplement. The NHS lists bleeding, infection, an allergic reaction to anaesthetic, scarring and transplanted hairs failing to take among hair-transplant risks. It also says the surgeon should explain how likely these problems are and how they would be treated (NHS: Hair transplant). Collagen research does not remove those risks or predict a surgical result.
Questions to ask the clinic
If collagen comes up during a discussion about thinning hair, ask:
- What diagnosis explains the hair loss, and who made that assessment?
- Does the evidence concern hair condition, shaft diameter, hair count or scalp density?
- Were participants diagnosed with the same type of hair loss, or did they have damaged hair without alopecia?
- Was the exact collagen product tested, including its source and formulation?
- Did the study compare the product with a placebo and report results beyond 24 weeks?
- Were the findings from people, isolated follicles, cultured cells or mice?
- If surgery is proposed, who will assess suitability and perform each stage?
Talk it through
If the cause of your hair loss has been professionally assessed and you want to understand whether surgery belongs among your options, GetHair can arrange a free consultation with a partner clinic. The partner clinic makes the clinical assessment and any treatment decision.